FDA slows down on drug reviews, approvals amid Trump admin. chaos

The Food and Drug Administration (FDA) is currently grappling with a noticeable slowdown in the review and approval of new drugs. This decline has been attributed to the tumultuous environment within the agency during the Trump administration, characterized by significant job cuts and a wave of leadership departures. According to an analysis conducted by RBC Capital Markets and reported by Stat News, the percentage of drugs approved by the FDA fell to 73% in the third quarter, marking a sharp drop of 14 percentage points from the average approval rate of 87% over the preceding six quarters. Furthermore, the agency has also seen an increase in the rate of missed deadlines for drug application reviews, which has surged from 4% to 11%. The trend continues as the FDA has rejected more applications than usual, with the rejection rate climbing from a historical average of 10% to 15% in the last quarter. Many of these rejections have been linked to issues at manufacturing facilities, raising concerns about the effectiveness of the FDA's inspection and auditing procedures. The situation is expected to worsen as the government enters a shutdown, leaving the FDA unable to accept new drug submissions despite continuing work on existing applications. This combination of challenges casts a shadow over the agency's ability to fulfill its critical role in ensuring drug safety and efficacy.